Featured Story | By Amirah Al Idrus Junshi’s PD-1 blocker is already approved in China for metastatic melanoma. But it’s not stopping there—it plans to add other cancer types to the drug’s label, starting with throat cancer. The drug, along with a standard-of-care chemotherapy duo, beat chemo alone at staving off cancer progression in patients with nasopharyngeal carcinoma, teeing up a regulatory filing. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Orgenesis has struck a deal to acquire Koligo Therapeutics. The takeover will give Orgenesis control of an autologous cell therapy treatment for respiratory disease caused by COVID-19. read more By Amy Sokolow Dewpoint Therapeutics, which launched in 2018 in both Cambridge, Massachusetts, and Dresden, Germany, aims to develop drugs against biomolecular condensates, poorly understood organelles that have been untapped as drug targets. The series B funding will bankroll the development of Dewpoint's platform and the identification of new drug candidates. read more By Nick Paul Taylor TriSalus Life Sciences has named Steven Katz, M.D., as its chief medical officer. The appointment gives Katz the chance to apply his experience as clinical investigator on solid tumor clinical trials to a pipeline led by TLR9 agonist SD-101. read more By Amirah Al Idrus When Neil Kumar, Ph.D., started BridgeBio Pharma in 2015, he met a lot of rejection. Investor after investor passed on his idea: picking up rare disease treatments “lying fallow” in academia and developing enough of them simultaneously that they would make money. Now, five years, an IPO and more than 20 programs later, BridgeBio is showing its backers what it’s made of. read more By Conor Hale LabCorp has signed a new, five-year agreement to license a blood test from Genfit designed to identify patients with risky cases of nonalcoholic steatohepatitis, also known as NASH. read more By Arlene Weintraub Cancer cells survive and proliferate with the help of nutrients and other materials that reach the cell nucleus via the “nuclear pore complex”—a door of sorts that’s vital for tumor survival. A team at Sanford Burnham Prebys Medical Discovery Institute has early evidence that blocking those doors can slow tumor growth. read more By Eric Sagonowsky With a pandemic spreading globally, vaccines have moved to the forefront of the public’s attention—naturally focused on COVID-19 candidates moving at record speeds. But biopharma companies haven’t given up on their other promising programs. These are the top late-stage vaccine prospects in pipelines today. read more Resources Sponsored by: LabVantage Want to leapfrog lengthy LIMS deployments and position your pharmaceutical lab for success? Find out how with LabVantage Solutions. Sponsored by: Blue Matter Consulting Senior executives from 16 biopharma companies share their thoughts on how COVID-19 will change how the industry engages with its customers. Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: EVERSANA How independent drug launch and commercialization can lead to higher market capitalization. Sponsored by: AMRI Download our white paper to learn more about the growth trends, complex anatomy and intricacies of developing these armed antibodies, as well as AMRI’s approach to their discovery and development. Sponsored by: LexisNexis Risk Solutions Avoid severe compliance penalties by staying on top of evolving laws. Sponsored by: Quotient Sciences This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging. Download now >> Sponsored by: Clarify Health In 2020, QED Therapeutics launched first-in-class infigratinib for cholangiocarcinoma (CCA). Learn how the launch team precisely identified and characterized eligible patients by taking an evidence-based approach to its commercial strategy. Sponsored by: Benchling Life science R&D generates a LOT of data. Learn how to make sense of it and harness its potential with this step-by-step guide. Sponsored by: Thermo Fisher Scientific Don’t oversimplify your solubility challenges. Sponsored by: Clinical Ink Download this free whitepaper to learn how to execute fast, high-quality clinical trials through eSource for studies that boost efficiency for both sponsors and sites. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
.jpg)
